ID27377A - Bentuk baru dari irbesartan, proses pembuatannya dan komposisi farmasi yang mengandung irbesartan tersebut - Google Patents

Bentuk baru dari irbesartan, proses pembuatannya dan komposisi farmasi yang mengandung irbesartan tersebut

Info

Publication number
ID27377A
ID27377A IDW20002738A ID20002738A ID27377A ID 27377 A ID27377 A ID 27377A ID W20002738 A IDW20002738 A ID W20002738A ID 20002738 A ID20002738 A ID 20002738A ID 27377 A ID27377 A ID 27377A
Authority
ID
Indonesia
Prior art keywords
irbesartan
making
new form
pharmacy composition
pharmacy
Prior art date
Application number
IDW20002738A
Other languages
English (en)
Inventor
Bruno Franc
Christian Hoff
Sam Kiang
Mark D Lindrud
Oliver MONNIER
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9527829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID27377(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of ID27377A publication Critical patent/ID27377A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
IDW20002738A 1998-06-24 1999-06-10 Bentuk baru dari irbesartan, proses pembuatannya dan komposisi farmasi yang mengandung irbesartan tersebut ID27377A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9808037A FR2780403B3 (fr) 1998-06-24 1998-06-24 Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant

Publications (1)

Publication Number Publication Date
ID27377A true ID27377A (id) 2001-04-05

Family

ID=9527829

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20002738A ID27377A (id) 1998-06-24 1999-06-10 Bentuk baru dari irbesartan, proses pembuatannya dan komposisi farmasi yang mengandung irbesartan tersebut

Country Status (25)

Country Link
US (2) US6800761B1 (id)
EP (1) EP1089994B9 (id)
JP (1) JP2002518495A (id)
KR (1) KR20010034917A (id)
CN (1) CN1127499C (id)
AT (1) ATE275562T1 (id)
AU (1) AU747887B2 (id)
BG (1) BG105069A (id)
BR (1) BR9912198A (id)
CA (1) CA2335545A1 (id)
CZ (1) CZ292868B6 (id)
DE (1) DE69920017T2 (id)
EA (1) EA003410B1 (id)
FR (1) FR2780403B3 (id)
HU (1) HUP0103913A3 (id)
ID (1) ID27377A (id)
IL (1) IL140419A0 (id)
NO (1) NO317786B1 (id)
NZ (1) NZ508842A (id)
PL (1) PL345215A1 (id)
SK (1) SK20032000A3 (id)
TR (1) TR200003842T2 (id)
UA (1) UA55540C2 (id)
WO (1) WO1999067236A1 (id)
ZA (1) ZA200007588B (id)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176793A1 (en) * 2001-12-10 2005-08-11 Reddy Reguri B. Amorphous form of 2-n-butyl-3-((2-(1h-tetrazol-5-yl)([1,1'-biphenyl)-4-yl)methyl)-1, 3-diazaspiro(4,4')non-1-en-4-one
WO2004065383A2 (en) 2003-01-16 2004-08-05 Teva Pharmaceutical Industries Ltd. Novel synthesis of irbesartan
GB0301259D0 (en) * 2003-01-20 2003-02-19 Novartis Ag Organic compounds
AU2007202693B2 (en) * 2003-01-20 2009-12-10 Novartis Ag Process for modifying drug crystal formation
DE602004015071D1 (de) * 2003-02-05 2008-08-28 Teva Pharma Synthese von 2-butyl-3-(2'-(1-trityl-1h-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro-4,4 -nonen-4-on
EP1660435A2 (en) * 2003-08-27 2006-05-31 Boehringer Ingelheim International GmbH Cycloalkylaminoacid compounds, processes for making and uses thereof
EP1751123A4 (en) * 2004-05-20 2010-06-30 Reddys Lab Ltd Dr PROCESS FOR PREPARING IRBESARTAN
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
SI21849A (sl) * 2004-07-29 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava hidrokloridnih soli tetrazolskega derivata
SI21848A (sl) * 2004-07-29 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava seskvihidratne hidrokloridne soli tetrazolskega derivata
TWI346108B (en) * 2004-08-23 2011-08-01 Bristol Myers Squibb Co A method for preparing irbesartan and intermediates thereof
GB2419592A (en) 2004-10-26 2006-05-03 Cipla Ltd Process for the preparation of irbesartan hydrochloride
WO2006050923A1 (en) * 2004-11-11 2006-05-18 Lek Pharmaceuticals D.D. Polymorph form of irbesartan
PL1806130T3 (pl) 2006-01-09 2010-08-31 Krka D D Novo Mesto Kompozycja farmaceutyczna w postaci stałej zawierająca irbesartan
WO2008041957A1 (en) * 2006-10-03 2008-04-10 Ulkar Kimya Sanayi Ve Ticaret As Method for producing pure crystalline form of 2-n-butyl-3-((2-(1h-tetrazole-5-yl) (1,1'-biphenyl)-4-methyl)-1,3-diazapspiro (4,4') non -1- en-4-one
ES2315141B1 (es) * 2006-11-23 2009-12-22 Quimica Sintetica, S.A Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
US20100104640A1 (en) * 2007-04-17 2010-04-29 Ratiopharm Gmbh Pharmaceutical compositions comprising irbesartan
CN101801371B (zh) * 2007-09-10 2012-11-28 詹森药业有限公司 可用作sglt抑制剂的化合物的制备方法
PT2065035E (pt) 2007-11-28 2010-10-04 Lesvi Laboratorios Sl Formulações farmacêuticas contendo irbesartan
EP2215083A2 (en) * 2007-12-07 2010-08-11 Hetero Drugs Limited Process for pure irbesartan
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
CZ302407B6 (cs) * 2009-03-12 2011-05-04 Univerzita Pardubice Zpusob prípravy 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-onu
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
KR101532412B1 (ko) * 2009-07-10 2015-06-29 얀센 파마슈티카 엔.브이. 1-(β-Ｄ-글루코피라노실)-4-메틸-3-(5-(4-플루오로페닐)-2-티에닐메틸) 벤젠의 결정화 방법
AR078107A1 (es) * 2009-08-31 2011-10-12 Sanofi Aventis Uso de irbesartan para la preparacion de un medicamento para la prevencion de la hospitalizacion por insuficiencia cardiaca
SG10201500258WA (en) * 2009-10-14 2015-03-30 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
LT2568988T (lt) 2010-05-11 2016-09-12 Janssen Pharmaceutica, N.V. Farmacinės kompozicijos, apimančios 1-(beta-d-gliukopiranozil)-2-tienilmetilbenzeno darinius kaip sglt inhibitorius
AU2012241897C1 (en) 2011-04-13 2017-05-11 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
HRP20200755T1 (hr) * 2015-12-21 2020-07-24 Janssen Pharmaceutica N.V. Postupak kristalizacije za dobivanje kristala kanagliflozin hemihidrata

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT97078B (pt) * 1990-03-20 1997-07-31 Sanofi Sa Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
FR2725987B1 (fr) 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive

Also Published As

Publication number Publication date
ATE275562T1 (de) 2004-09-15
CA2335545A1 (en) 1999-12-29
TR200003842T2 (tr) 2001-06-21
WO1999067236A1 (fr) 1999-12-29
KR20010034917A (ko) 2001-04-25
EA200001221A1 (ru) 2001-08-27
BR9912198A (pt) 2001-04-10
NO317786B1 (no) 2004-12-13
EA003410B1 (ru) 2003-04-24
HUP0103913A3 (en) 2003-01-28
IL140419A0 (en) 2002-02-10
NZ508842A (en) 2002-09-27
FR2780403A1 (fr) 1999-12-31
AU747887B2 (en) 2002-05-30
BG105069A (en) 2001-11-30
US7008959B2 (en) 2006-03-07
NO20006645L (no) 2001-02-26
DE69920017T2 (de) 2005-09-22
PL345215A1 (en) 2001-12-03
CN1127499C (zh) 2003-11-12
FR2780403B3 (fr) 2000-07-21
US6800761B1 (en) 2004-10-05
UA55540C2 (uk) 2003-04-15
CZ20004771A3 (en) 2001-06-13
SK20032000A3 (sk) 2001-05-10
US20050032862A1 (en) 2005-02-10
EP1089994A1 (fr) 2001-04-11
HUP0103913A2 (hu) 2002-03-28
EP1089994B1 (fr) 2004-09-08
CN1306529A (zh) 2001-08-01
ZA200007588B (en) 2001-06-11
NO20006645D0 (no) 2000-12-22
JP2002518495A (ja) 2002-06-25
AU4048499A (en) 2000-01-10
CZ292868B6 (cs) 2003-12-17
EP1089994B9 (fr) 2008-08-27
DE69920017D1 (de) 2004-10-14

Similar Documents

Publication Publication Date Title
IL140419A0 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
ID24730A (id) Senyawa-senyawa heterosiklik untuk penghambatan sekresi asam lambung, proses pembuatan dan komposisi-komposisi farmasinya
MXPA05010682A (es) Compuestos novedosos.
AU2002358667A1 (en) Scented polymer capsules and the production thereof
IL117091A0 (en) Methylphenyloxazolidinone derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
HUP0201909A3 (en) Aminobenzophenones as inhibitors of il-1betha and tnf-alpha, process for producing them and pharmaceutical compositions containing them
IS6859A (is) Kristölluð form atorvastatíns
NZ523446A (en) (Aminoalkylbenzoyl) benzofuran or benzothiophene, their process of prepation and the compositions comprising them
GB0216001D0 (en) Process and composition
ATE334993T1 (de) Hydratformen des natriumsalzes von alendronat, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese enthalten
ATE430160T1 (de) Lipopeptid-stereoisomere, verfahren zu ihrer herstellung und nützliche zwischenprodukte
IL174469A0 (en) Rearranged pentanols, a method for the production thereof, and their use as antiphlogistics
AU2003239793A1 (en) Alicyclic esters having a musky smell
WO2003037863A3 (de) Substituierte indole, verfahren zu deren herstellung und deren verwendung zur schmerzbekämpfung
HUP9601321A2 (en) Substituted (benzyloxy)-carbonyl-guanidine derivatives, process for producing them, pharmaceutical compositions containing them their use as pharmaceutical compositions or diagnostica, and the use of the said compds.
MY120085A (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines.
ATE281434T1 (de) Verfahren zur herstellung von benzoperhydroisoindolen
MXPA02012112A (es) Composiciones que contienen policarbonato.
DE50208851D1 (de) Gelierzucker und verfahren zu dessen herstellung
DE69926223D1 (de) Verfahren zur herstellung von zwischenprodukten
NO20031137L (no) Foreliggende oppfinnelse angår en fremgangsmåte for fremstilling av kiraleforbindelser under betingelsene for en 1,4-Michael-addisjon.Oppfinnelsen angårogså de tilsvarende forbindelser
PL353291A1 (en) Novel compounds, method of obtaining them, their application as pigments and composition containing them
AU1298800A (en) Process of preparing a high-energy softening agent
ATE259784T1 (de) Propanolaminotetraline, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende pharmazeutische zusammensetzungen
MEP56208A (en) Caloporoside derivatives, methods for the production thereof and their use